Hoth Therapeutics Reports Positive HT-VA CRADA Data
Hoth Therapeutics reports positive HT-VA data showing GDNF improves liver fat metabolism, reduces fat production and may outperform semaglutide in MAFLD and obesity.
Robb Knie | 14/04/2026 | By News Bureau
Hoth Therapeutics Expands Phase IIa CLEER-001 Trial with New Miami Site
Hoth Therapeutics, Inc. has expanded its Phase IIa CLEER-001 trial with a new Miami site after promising interim results for HT-001 in managing skin toxicities linked to EGFR inhibitor cancer therapy.
Robb Knie | 26/02/2026 | By News Bureau | 107
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy